摘要
目的检测Her-2／neu蛋白和雄激素受体（androgenreceptor，AR）在前列腺癌组织中的表达情况，探讨其在前列腺癌发生发展中的意义。方法构建前列腺病变的组织芯片，其中包括前列腺癌107例（Gleason评分6分29例，7分20例，8分46例，9分12例），良性前列腺组织42例；采用EnVsion两步法进行Her-2／neu蛋白和AR的免疫组织化学染色，分析其在前列腺癌及良性前列腺组织中的差异；从免疫组织化学染色强度及阳性细胞数两个方面评价蛋白表达情况，分析其与前列腺癌Gleason评分的关系。结果Her-2／neu蛋白在前列腺癌组织中的阳性表达率为43．9％，高于在良性前列腺组织中的阳性表达率（14．3％）（x2=11．562，P=0．009），其阳性表达强度前列腺癌高于良性前列腺组织（x2=11．764，P=0．008）。在不同Gleason评分组中，Her-2／neu蛋白的阳性表达强度差异有统计学意义（x2=20．512，P=0．015），且与Gleason评分呈正相关（r=0．269，P=0．005）。前列腺癌组织AR阳性表达率（67％）高于良性前列腺组织（50％）（x2=3．843，P=0．050），但其阳性表达强度在前列腺癌及良性前列腺组织中的差异无统计学意义（x2=4．318，P=0．229）。在不同Gleason评分组中AR的阳性表达强度差异无统计学意义（x2=13．385，P=0．146），与Gleason评分无相关性（r=-0．065，P=0．505）。前列腺癌组织中Her-g／neu蛋白和AR的阳性表达强度无相关性（r=-0．115，P=0．237）。结论Her2／neu蛋白在前列腺癌中的高表达提示其可能在前列腺癌发生中起一定作用。Her-2／neu蛋白的阳性表达强度与Gleason评分呈正相关，提示Her-2／neu蛋白与前列腺癌的预后有一定的相关性。
Objective To observe the expression of Her-2/neu protein and androgen receptor （AR） in human prostate cancer and to evaluate their signifieances in the progression of prostate cancer. Methods The Her-2/neu protein and AR immunohistochemical stain were carried out in human prostate tissue mieroarray that consisted of prostate cancer （107 cases） and benign prostate tissue （42 cases）. The prostate cancer cases were divided into 4 groups： group one （Gleason score 6）, group two （Gleasonscore 7）, group three （Gleasonseore 8） and group four （Gleasonscore 9） according to the Gleason score. The immunostains immunohistochemieal stain were interpreted in two aspects of the staining intensity and the percentage of positive cells. The significance and relationships between the expression of Her-2/neu protein and AR in prostate cancer and benign prostate tissue （BPT） and the grouping of different Gleason scores of prostate cancer were then evaluated. Results The positive expression rate of Her-2/neu protein was significantly higher in prostate cancer tissue than in BPT [/13.9%（47/107） vs 14.3% （6/42）, x2 = 1l. 562, P = 0. 0099, and the positive expression intensity of Her-2/neu immunoreactivity was also higher （x2= 11.764, P=0.008）. There were significant differences in positive expression intensity of Her- 2/neu immunoreactivity among the different Gleason scores groups （X2 = 20.512, P = 0.015）, and the expression intensity was significantly positively correlated with Gleason scores （r= 0. 269, P = 0. 005 ）. There was significant difference in AR immunoreactivity between in prostate cancer （67%, 72/107） and in BPT （50%, 21/ 42, x2=3.843, P=0.050）. Among prostate cancer cases, the positive expression intensity of AR was not significantly different among groups 1 through 4 （x2 = 4. 318, P = 0. 229）, and was not significantly correlated with Gleason scores （ r = -- 0.0（35, P = 0. 505 ） . Moreover, the positive expression intensity of Her-2/neu protein was n
出处
《中华老年医学杂志》
CAS
CSCD
北大核心
2011年第8期671-675,共5页
Chinese Journal of Geriatrics
基金
基金项目：江苏省“135工程”医学重点学科基金
2006年度人事部留学回国人员科技活动项目择优资助启动类经费及南京市医学科技发展课题经费（YKK06087）
